<img alt="" src="https://secure.agile-company-247.com/261975.png" style="display:none;">

 Longevity Leaders Logo White

Longevity_Leaders_Logo White


4th Annual Congress
In-Person Event -
26-27th April 2022
etc.venues, 133 Houndsditch, Liverpool St.
London, EC3A 7BX




Created by    LSX

Longevity science & regenerative medicine

Regenerative medicine is going from strength to strength, with over 50 RMAT designations in the US to date, successful development of autologous stem cell treatments and renewed interest from the aesthetics industry. Gene therapies continue to show promise and inch closer to adoption. It is an incredibly exciting time to be a part of the growing longevity community with cell & gene pioneers expanding age-related solutions such as novel neural stem cell therapy, muscle tissue constructs and gene modifiers for macular degeneration.

Meanwhile longevity science is at a critical moment in time. In the wake of the COVID-19 pandemic investors, regulators and the medical community have woken up to the promise of ageing science and its potential to completely change how we prevent and treat disease. Advanced analytical tools are driving huge strides in our understanding of ageing biology and potential targets, and a number of high-profile fund raises are driving investor interest in the space.

Regenerative medicine and longevity therapeutics have both come a long way in recent years and set for the next decade of innovation, particularly with both gaining from parallel advancements in ageing science. The deeper understanding in cellular senescence, identification of aging genes, tissue engineering constructs and advancements in RNA modulation are all allowing longevity science and cell & gene therapies space to learn and innovate together.

The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases. We’d love you to join us!

Longevity science & regenerative medicine


“A tremendous event!”
Omair Ahmed, Founder & Chief Product Officer, Neurometry


Meet our speakers

Ben Turner Director- Venture Science, Europe Lilly New Ventures Corporate Business Development Eli Lilly and Company

Ben Turner

Director - Venture Science, Europe Lilly New Ventures Corporate Business Development
Eli Lilly
Thomas Rando, Co-Founder, Fountain Therapeutics

Thomas Rando

Fountain Therapeutics
Greg Bailey, CEO, Juvenescence

Greg Bailey

Joshua Hare

Joshua Hare

Co-Founder & CSO
Longeveron LLC
Tea Shavlakadze, Director, Regeneron Pharmaceuticals Inc

Tea Shavlakadze

Director of Aging/Age-Related Disorders
Regeneron Pharmaceuticals
Juliette Han, Ph.D., Chief Operating Officer, Cambrian

Juliette Han

Chief Operating Officer
Cambrian Biopharma
David Weinkove, CEO, Magnitude Biosciences

David Weinkove

Magnitude Biosciences
Sibylle Jager, Scientific Directorate Manager, L’Oréal

Sibylle Jager

Scientific Directorate Manager
Jamie Dananberg, Chief Medical Officer, UNITY Biotechnology

Jamie Dananberg

Chief Medical Officer
Unity Biotechnology
Lorna Harries, Chief Scientific Officer, Senisca

Lorna Harries

Chief Scientific Officer
Alexandra Sharon-Bause, Co-Founder, Investment Director and Head of VentureLabs, Apollo Health Ventures

Alexandra Bause

Co-Founder, Investment Director &Head of VentureLabs
Apollo Ventures
Patrick Burgermeister, Partner Kizoo Technology Capital

Patrick Burgermeister

Kizoo Technology Capital
Nir Barzilai, Director,  Institute for Aging Research, Albert Einstein College of Medicine

Nir Barzilai

Director, Institute for Aging Research
Albert Einstein College of Medicine
Georgina Ellison-Hughes, Professor of Regenerative Muscle Physiology, Kings College London

Georgina Ellison-Hughes

Professor of Regenerative Muscle Physiology
King’s College London
Janet Lord Institute of Inflammation and Ageing, University of Birmingham

Janet Lord

Institute of Inflammation and Ageing
University of Birmingham
Georg C. Terstappen, Ph.D., EVP, Drug,Cambrian  Discovery

Georg C. Terstappen,

EVP, Drug Discovery
Cambrian Biopharma



Longevity therapeutics market expected to reach $524 million by 2027


More than £1 billion invested in longevity biotech to date


3000+ longevity and regenerative medicine biotechs worldwide

Cell and gene therapy market is forecast to reach $45 billion by 2028

£8.25 billion raised by cell and gene therapy companies in 2020

54 RMAT (Regenerative Medicine Advanced Therapy) designations to date from the FDA

5000+ investors committing to longevity and regenerative medicine

More than 13,330 active cell therapy trials ongoing

667 active clinical trials for ageing as a disease worldwide

Gold partners



Silver partners



EY Logo-1

Magnitude Biosciences



Bronze partners


Genflow Biosciences Logo

genome protection inc

Longevity Tech Fund logo



Female Founders

Networking, Dialogue And Mentorship For Women In Health And Life Sciences
Members save 25% off all LSX events.


Subscribe to hear speaker announcements, ticket offers and more